T-cell responses after COP Immunotherapy to be Presented at EAACI Congress 2017
- Delineation of T cell responses after COP Immunotherapy in birch pollen allergic patients
EPALINGES, Switzerland, June 13, 2017 – Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today that new mechanistic data using its lead-product AllerT for the treatment of patients allergic to birch pollen, will be presented by Dr Pawel Gajdanowicz of the Department of Clinical Immunology, Wrocław Medical University, Wrocław, Poland at the EAACI Congress 2017 in Helsinki, Finland.
The studies reported were conducted in collaboration between “ALL-MED” Medical research Institute, Wrocław, the Department of Clinical Immunology, Wrocław Medical University and Anergis SA, on samples collected from a previous clinical trial during which birch allergic patients received either AllerT or placebo.
Today, AllerT is the only ultra-fast AIT treatment with demonstrated clinical efficacy in real-life field-based trials over two consecutive annual pollen seasons and with persistent statistically significant elevation in specific immunoglobulin G4 (IgG4) over four consecutive annual pollen seasons, without repeated treatment after the initial 2-month course.
Anergis SA is currently conducting a large-scale field-based trial with AllerT called ATIBAR, the results of which are expected to be available during Q3 2017.
Presentation Title: "Delineation of T cell responses after COP Immunotherapy in birch pollen allergic patients"
Presenter: Pawel Gajdanowicz
Time and Date: Tuesday, June 20, 2017, 12.00 pm - 1.30 pm
Session: TPS 51 - Immune response and mechanisms of allergy
Poster #: 1340
Location: Thematic Poster Exhibition, Messukeskus, Helsinki Finland